A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease. WHY IT'S IMPORTANT ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Eli Lilly has raised its revenue guidance for 2024 by $3 billion, after reporting strong growth for tirzepatide in diabetes and obesity, fuelled by the end of supply constraints for starting doses.